Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 57.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (33.1%)
  • Dividend yield for the last twelve months 0.7%
  • Free cash flow yield -1.5% (LTM)
  • Share price is 165.7% higher than minimum and 14.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (40.8x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $979.9 mln (-0.133% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (+0.5%)825.45
year average price 787.85  


year start price 892.70 2024-10-26

max close price 929.72 2025-03-03

min close price 625.65 2025-08-08

current price 825.45 2025-10-26
Common stocks: 900 605 000

Dividend Yield:  0.7%
FCF Yield LTM: -1.5%
EV / LTM EBITDA: 40.8x
EV / EBITDA annualized: 26.5x
Last revenue growth (y/y):  +37.6%
Last growth of EBITDA (y/y):  +77.9%
Historical revenue growth:  +23.8%
Historical growth of EBITDA:  +42.3%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 743 404
Net Debt ($m): 36 434
EV (Enterprise Value): 779 838
EBITDA LTM ($m): 19 131
EV / LTM EBITDA: 40.8x
Price to Book: 52.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-10-24prnewswire.com

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

2025-10-24fool.com

2 Things Investors Should Know About Eli Lilly's $5 Billion Investment to Improve Its Drug Production Capacity

2025-10-23zacks.com

Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?

2025-10-23reuters.com

Eli Lilly allows Cipla to sell weight loss drug under new brand in India

2025-10-19fool.com

J.L. Bainbridge Buys $45 Million in Eli Lilly Stock Despite Price-Pressure Fears

2025-10-19fool.com

Investment Advisor Goes All-In on Big Pharma Stock to the Tune of $1.07 Billion, According to Recent Filing

2025-10-17seekingalpha.com

3 Price Catalysts For Eli Lilly

2025-10-17fool.com

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?

2025-10-14fool.com

1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today

2025-10-13prnewswire.com

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data